Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.

Trial Details

NCT ID

NCT04643002

Phase

PHASE1 / PHASE2

Sponsor

Sanofi

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

Isatuximab
Dexamethasone
Pomalidomide
Belantamab mafodotin
Pegenzileukin
SAR439459

Locations (sample)

Atlanta, Georgia, United States|33.749,-84.38798
Chicago, Illinois, United States|41.85003,-87.65005
Ann Arbor, Michigan, United States|42.27756,-83.74088
Buffalo, New York, United States|42.88645,-78.87837
Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

Participant must be 18 years of age inclusive or older.
Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
Participants with relapsed or refractory MM who have received at least 2 prior lines of therapy for MM, including PIs and IMiDs (eg, Induction regi…
RRMM with measurable disease:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →